Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

French pharma major Sanofi (Euronext: SAN) today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to ...

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Quarterly Net Profit at Rs. 91.30 crore in December 2024 down 33.7% from Rs. 137.70 crore in December 2023. EBITDA stands at ...

Banks are gearing up to offload the €8.65 billion ($9.5 billion) debt package backing Clayton Dubilier & Rice’s purchase of a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...